Skip to main content
. 2021 Nov 24;100(47):e27954. doi: 10.1097/MD.0000000000027954

Figure 2.

Figure 2

Forest plots for overall survival pooled hazard ratio (A), progression-free survival pooled hazard ratio (B) and objective response rate pooled odds ratio (C): Chemotherapy plus anti-EGFR-mAb versus chemotherapy alone for advanced NSCLC. NSCLC = non-small-cell lung cancer; anti-EGFR-mAb = anti-epidermal growth factor receptor monoclonal antibody; CI = confidence interval; SE = standard error; Ch2 = chi-squared test; df = degree of freedom; I2 = I-squared.